Nature Medicine, Published online: 23 October 2026; doi:10.1038/s41591-026-04711-0 As presented at the European Society for Medical Oncology Congress 2026, in a phase 1/2 trial in participants with solid tumors, invika, a first-in-class bispecific agonistic antibody that selectively targets the prevalent Vβ6/Vβ10 T cell subsets, was well tolerated, enabling the selection of a recommended phase 2…
Consumer sentiment in the U.K. tumbled at the fastest pace since the Covid-19 pandemic this month as mounting cost-of-living pressures reversed the bounce in optimism seen over the summer.
